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Modern health care in the field of Medicine, Dentistry and Nursing is grounded in fundamental philosophy and
epistemology of translational science. Recently in the U.S major national initiatives have been implemented in the
hope of closing the gaps that sometimes exist between the two fundamental components of translational science,
the translational research and translational effectiveness. Subsequent to these initiatives, many improvements have
been made; however, important bioethical issues and limitations do still exist that need to be addressed. One such
issue is the stakeholder engagement and its assessment and validation. Federal, state and local organizations such
as PCORI and AHRQ concur that the key to a better understanding of the relationship between translational research
and translational effectiveness is the assessment of the extent to which stakeholders are actively engaged in the
translational process of healthcare. The stakeholder engagement analysis identifies who the stakeholders are, maps
their contribution and involvement, evaluates their priorities and opinions, and accesses their current knowledge base.
This analysis however requires conceptualization and validation from the bioethics standpoint. Here, we examine the
bioethical dilemma of stakeholder engagement analysis in the context of the person-environment fit (PE-fit) theoretical
model. This model is an approach to quantifying stakeholder engagement analysis for the design of patient-targeted
interventions. In our previous studies of Alzheimer patients, we have developed, validated and used a simple instrument
based on the PE-fit model that can be adapted and utilized in a much less studied pathology as a clinical model that
has a wide range of symptoms and manifestations, the temporomandibular joint disorders (TMD). The
temporomandibular joint (TMJ) is the jaw joint endowed with sensory and motor innervations that project from
within the central nervous system and its dysfunction can be manifested systemically in forms of movement
disorders, and related pathological symptomatologies.
Currently, there is limited reliable evidence available to fully understand the complexity of the various domains of
translational effectiveness, particularly in the context of stakeholder engagement and its assessment, validation as
well as the bioethical implications as they pertain to evidence-based, effectivness-focused and patient-centered care.
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The Patient Protection and Affordable Care Act (PPACA-
2010) [1] seeks to improve healthcare in the U.S., but it
contains many controversial flaws and limitations. The
pursuit of translational medicine, dentistry and nursing is
based on the fundamentals of translational science, which
is composed of two domains, the translational research
and the translational effectiveness. Translational research
refers to the scientific research the “bench-to-bedside” en-
terprise of translating knowledge from the basic sciences
into the development of new treatments. It is the move-
ment between basic research and patient-oriented research
that leads to new or improved scientific understanding.
Translational effectiveness refers to translating the findings
and results into everyday practice. It facilitates the move-
ment between patient-oriented research and population-
based research that leads to better patient outcomes, the
implementation of best practices, and improved health
status for patients and communities. Together they adhere
to the hypothesis-driven scientific process that involves an
intimate transaction of the systematic process of patient-
centered outcomes research on the molecular and systems
pathobiology of the patient, as well as the research synthe-
sis process for the consensus of the best available evidence
in patient-targeted interventions. Translational science as
a whole aims to increase health literacy of the patients,
caregivers and other stakeholders, which in turn de-
mands significant improvements in evidence dissemin-
ation empowering them to actively participate in the
decision-making process. However, a clear, well defined
and bioethically sound procedural methodologies are still
missing for assessing, evaluating and analyzing stake-
holder engagement. Here, we examine this question in
patients with Temporomandibular Joint Disorders (TMD)
as a clinical model, because, while this pathology com-
mences as a problem related to the field of dentistry, it
can lead to systemic manifestations that involve medicine
and nursing. We propose that stakeholder engagement
analysis in translational science is bioethically sound, so
long as it contributes to the psycho-cognitive, psycho-
emotional accommodation and well being of the stake-
holder in the reality of the clinical condition at hand [2].
The temporomandibular joint
The temporomandibular joints are ginglymo-arthrodial
bilateral articulations of the mandible with the maxillary
bone of the frontal aspect of the skull, with a hinge-type
ginglymal and a sliding arthrodial component. Encapsu-
lated by a fibrous tissue, each joint consists of the con-
dylar process of the mandible below, and the glenoid
fossa of the temporal bone above. Between these bone
surfaces lies the articular meniscal disc, held by tight fi-
bers from below and looser fibers from the temporal
bone superiorly, which creates an upper and a lowercapsular space. A synovial membrane lines the inner
facet of the capsules, and secretes the temporomandibu-
lar synovium that fills and lubricates the upper and
lower spaces [3]. When adequate support by the relative
occlusional position of the upper and lower teeth, the
molars in particular, is lacking, the joint is progressively
and chronically altered anatomically due to deregulated
functions of masticatory muscles, which contributes to
temporomandibular joint pathology [3].
The trigeminal nerve, the largest of the twelve cranial
nerves is responsible for sensation in the head and neck.
Of its three branches, the mandibular branch innervates
the lower face and the temporomandibular joint. It pro-
jects somatic afferent fibers, and motor innervation to
the masticatory musculature (i.e., special visceral efferent
fibers) [3]. The trigeminal branches originate from the
trigeminal ganglion, whence a single large sensory root
enters the brainstem at the level of pons. A number of
cranial nerves converge to the pons, besides the mid-
pontine sensory and motor trigeminal projections. These
include the abducens nerve (cranial nerve VI), which
controls the lateral rectus muscle for movement of the
eye, the facial nerve (VII), which controls the muscles of
facial expression, and the vestibular-cochlear nerve (VIII),
which transmits sound and equilibrium (balance) informa-
tion from the inner ear to the brain. Together they impart
to the pons its sensory regulation of hearing, equilibrium
and movement, taste, and facial sensation to touch and
pain, as well as its motor regulatory function for eye
movement, facial expressions, chewing, swallowing, saliva
and tear secretion, as well as movement coordination [3,4].
Disorders of the temporomandibular joint encompass a
spectrum of diverse conditions, and the term TMD de-
scribes a group of conditions with similar signs and
symptoms that affect the termporomandibular joints, the
muscles of mastication, or both. TMD is often character-
ized by aching of the muscles of mastication, pain and
clicking or popping sounds upon opening and closing the
jaw, and severely restricted jaw movement. In our previous
studies, we showed that TMD contributes to the develop-
ment and exacerbation of cervical dystonia and other
movement disorders, most likely via neuritis of the auricu-
lotemporal branch of the trigeminal nerve that feeds into
the pontine region and controls head and body posture
[5]. In those studies we also proposed that the proteomic
signature of biomarkers in local (e.g., joint synovial fluid)
and distal body fluids (e.g., saliva, cerebrospinal fluid) in a
translational research modality would behoove patient-
targeted TMD diagnosis and prognosis [6,7]. Our data ob-
tained within the EBD-PBRN also indicated remarkable el-
evations in certain neuroimmune factors in the synovial
fluid of TMD patients that were significantly and posi-
tively correlated with diagnostic imaging-rated severity
of the TMD condition [8] (Barkhordarian et al., under
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munological and neuropathology complexities with TMD.
Stakeholders in translational medicine
Translational medicine rests on the fundamental princi-
ples of stakeholder engagement [2]. Stakeholders are im-
portant partners in the clinical decision-making process
[2,9,10], particularly in the context of patient-centered
healthcare home/neighborhoods for optimizing patient-
targeted interventions. However, the evidence on the ef-
fectiveness and the bioethics of stakeholder engagement
still remains to be limited [11,12].
Stakeholder theory originally defined stakeholders as
those individuals without whose support and feedback
an organization, or a project within an organization can-
not subsist [13]. In the context of translational medicine,
stakeholders are: basic scientists, clinicians/clinical re-
searchers, epidemiologists, health services researchers,
patients, family members, caregivers, patient advocates,
social workers, insurance carriers, legal advisers. They pro-
vide multidimensional contributions to patient-targeted
endeavors in evidence-based, effectiveness-focused clinical
decision-making processes [8,14]. As shown in Figure 1
stakeholders in modern healthcare engage in translational
medicine as:
1. Primary stakeholders: those individuals ultimately
and directly affected, either positively or negatively,
by the healthcare outcomes (e.g., patients, theFigure 1 Stakeholder matrix. The figure shows a simplified stakeholder m
the example provided in the figure, each stakeholder is identified as prima
and other characteristics are tabulated in the matrix, as well as the stakeho
example provided, we have a “friend”, who could be a secondary stakehold
possessing a Power of Attorney or directive who makes healthcare decision
be, at this present moment, relatively minor as visits are relatively rare. Yet,
the case that visits have a seriously detrimental outcome on the patient). T
revisited and updated.immediate family members, caregivers of patients
who cannot represent themselves),
2. Key stakeholders: individuals who may or may not
be primary stakeholders, but have a significant
influence on the decision-making process (e.g.,
relatives, friends or caregivers empowered by a legal
document or directive to make healthcare decisions
on behalf of the patient),
3. Secondary stakeholders: individuals indirectly
affected by the outcomes, or indirectly involved in
the patient’s care process,
4. Allied stakeholders: individuals who are involved in
the patient’s care, but are indirectly affected by the
healthcare outcome (e.g., medical, dental, nursing
and pharmacy staff, other hospital employees,
insurance agents, legal staff and lawyers).
The critical questions and issues of bioethics in trans-
lational medicine has remained to be addressed in part
because individuals who judge themselves to be stake-
holders engage de facto (in practice but not necessarily
ordained by law) as stakeholders raising issues of liability
and protection of the confidentiality and security of
health care information. Incontrovertible evidence estab-
lishes that stakeholder engagement is rarely uniform: not
all stakeholders have the same roles and degree of in-
volvement in the healthcare process. Therefore, assessing
stakeholder engagement (Table 1) while necessary and
critical for translational medicine may be bioethicallyatrix to exemplify the process of stakeholder “mapping”. As shown in
ry, key, secondary or allied. The stakeholder’s influence, role activity,
lder’s effect and outcome of the healthcare intervention process. In the
er identified in this case as a key stakeholder, presumably because of
s on behalf of the patient. We observe the influence of this friend to
we recognize beneficial outcomes from those visits (it could also be
his tabulation is prepared for every stakeholder, and is regularly
Table 1 The seven principal steps of stakeholder analysis
Steps
1 Defining: Stakeholders are defined and identified in relation to a specific issue: stakeholder identification operates in respect to a particular
specified issue.
2 Long Listing: A “long list” of key, primary and secondary stakeholders is drawn with respect to the specified issue that indicates groupings
(e.g., public, private, and community) and sub-groupings (i.e., gender, ethnicity, age).
3 Mapping: Analysis of the Long List along selected criteria (i.e., interest, social influence, political role) to allow systematic exploitation of
positive attributes, identification of gaps or needed bridge-building among stakeholders are mapped.
4 Visualizing: Drawing an Influence-Interest-Capacity matrix is essential at this stage.
5 Verifying: Validity of the analysis is established by assessing and verifying stakeholders availability and commitment. This step may require
additional informants and information sources.
6 Mobilizing: Strategies for sustaining effective participation of the stakeholders, tailored to the different groups and sub-groups of identified
stakeholders are mobilized and implemented that includes empowerment interventions for high stake stakeholders with little power
or influence.
7 Evaluating: Reassessment is performed to ensure maximizing the roles and contribution of all stakeholders.
Barkhordarian et al. Journal of Translational Medicine  (2015) 13:15 Page 4 of 7restricted, biased and compromised. There is a need for
concerted research efforts to be directed towards the de-
velopment and validation of novel analytical tools to es-
tablish the nature, level (or quantity), and quality of
stakeholder participation in healthcare [15].
Stakeholder analysis must evolve as systematic, sequen-
tial scientific process, subject to a stringent process of con-
struct validation designed to identify and characterize
sub-constructs related to stakeholder engagement. Stake-
holders’ roles, involvement and function must be quanti-
fied, including their (1) actions and position; (2) ability
and intent to influence implementation; (3) motivation to
participate; and (4) capability to change and adapt as the
care situation evolves, and calls for adaptive management
[2,16-18]. Reliable tools must be developed, as mentioned,
to that end, which must be bioethically coherent and con-
temporaneously validated to quantify stakeholders’ benefi-
cial input.
In order to assess the reliability of these novel instru-
ments, the analyses of inter-rater reliability and coeffi-
cient of agreement [2], as well as generalizability (G)
theory validation will be required. The generalizability
validation process ensures a flexible approach to simul-
taneously estimate multiple sources of measurement
error variance (i.e., facets), while permitting to generalize
the findings of the main analysis across the different
study facets. G theory leads to re-calculate the reliability
and minimal detectable changes across a variety of com-
bination conditions of these facets. In brief, the G mode
of validation of stakeholder engagement analysis will en-
gender the selection of optimal settings minimizing the
number of required measures [2,19].
In our preliminary studies (data not included) we have
examined the criteria and processes necessary to im-
prove stakeholder engagement by raising their health lit-
eracy. We were able to demonstrate that bioethically
sound training in communication skills could signifi-
cantly improve physicians-patient relationship, reduceinappropriate use of medical information, and raise stake-
holder engagement [20].The Person-Environment (PE) fit theoretical model
To best examine the role and fit of stakeholders in the
context of patient-targeted interventions in translational
medicine, we considered the well-established and validated
theoretical PE fit model. PE-fit establishes the degree to
which a person is compatible with the environment, and
determines the extent to which someone’s personality and
set of skills are adaptable with the environmental de-
mands. It defines the degree to which an individual can
successfully adjust to the imperatives of the surrounding.
The model arose from the Personality-Job Fit theory,
which states in brief that a person’s personality, training
and skills determine one’s adaptability and synergy in an
organization and a work environment. A perceived (i.e.,
subjective) or real (i.e., objective) misfit between the per-
son and environment leads to impaired outcomes on spe-
cific tasks, job performance, satisfaction and quality of
professional and personal life. From an analytical stand-
point, the model offers a framework for establishing and
predicting how the person’s real and perceived characteris-
tics and skills will fit and adapt to the real and perceived
requisites and demands of the work environment. Because
the perception of fit of an individual within a given envir-
onment is dependent upon one’s ability to discern between
perception and reality, the model reveals preventive inter-
vention toward improving the person’s well-being, should
it be sub-optimal due to constraining factors in the envir-
onment [2,21-23].
The model evolved to address outcomes of ill-health,
consequential to the psycho-emotional stress associated
with a perceived or real lack of fit, between an individual
and the environment. Further evolution rendered the
model more widely applicable across a variety of settings
in translational medicine, including our study of evidence-
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of patients with Alzheimer’s disease [24,25].
In that work, we constructed and validated a simple in-
strument (in-house questionnaire), based on the same cri-
teria described in the literature [21], which consisted of 15
components aimed at quantifying the subjective and ob-
jective perceptions of the caregivers and of the immediate
demands of the caregiving responsibilities (Table 2) [25].
The data were analyzed along four simple criteria:
 The principal subjective caregiver-environment fit:
fit between the subjective perception of the caregiver
and his/her perceived responsibilities;
 The secondary objective caregiver-environment fit:
fit between the objective abilities of caregiver in the
face of the objective demands of the caregiving
responsibilities;
 The reality contact: correspondence between the
subjective perception of the responsibilities of
caregiving and the objective reality posed by these
responsibilities; and
 The accuracy, or accessibility, of the self:
correspondence between the subjective views and
objective reality of the caregiver’ abilities to face
these demanding responsibilities.
The subjective person-environment fit (Fs) is the result
of the interdependent relationship between the person’s
subjective assessment of self (Ps) and his or her subject-
ive evaluation of the environment (Es). In a parallel fash-
ion, the objective environment (Eo) and the objectively
assessed person’s abilities to meet its demands (Po) yield
a quantification of the objective person-environment fit
(Fo). These relationships can be summarized quantitativelyTable 2 PE fit for caregivers of patients with Alzheimer’s dise
1 Overall perception of health
2 Perceived energy level
3 Perceived mood of patient
4 Perceived lifestyle of patient
5 Perceived memory of patient
6 Perceived family relationships
7 Perceived relationship with spouse
8 Perceived relationship with friends
9 Perceived sense of self
10 Ability to perform household chores
11 Enjoyment of leisure
12 Ability to hold financial responsibilities
13 Perception that own life is ending
14 Overall life satisfaction
15 Have intent to hurt selfas Fo = Eo-Po and Fs = Es-Ps, a can reflect the demand, or
need on the part of the person (Np), or the environment
(Ne) to actualize fit; and the given abilities of the person
(Gp), or the given attributes of the environment (Ge) that
facilitates fit. The objective person-environment fit (Fo)
is a complex function of the difference (delta, Δ) be-
tween the attributes of the environment (Ge) and the
need on the part of the person (Np) or the environment
(Ne) to actualize fit. In the same vein, subjective person-
environment fit (Fs) is a function of the delta between
the attributes of the person (Gp) and the need of the en-
vironment (Ne) to facilitate fit.
The validity and the reliability of the instrument were
tested in 200 subjects stratified, based on clinical exam
among the groups of senile dementia of the Alzheimer’s
type of stages 1–5 on the Global Assessment Scale (age
range: 55–70), and of age-matched non-Alzheimer’s type
dementias that included vascular dementias, Parkinson’s
dementia, and dementia with Lewy bodies. We also in-
cluded control subjects with no signs of dementia and of
the same age range. Taken together, the inferences de-
rived from this simple instrument provided a critical
element to ensure optimal utilization of caregivers in the
patient-targeted evidence-based clinical intervention for
patients with Alzheimer’s disease [25].
Currently we are in the process of developing a new
instrument (questioner) in order to incorporate bio-
ethical issues in the assessment of the stakeholder en-
gagement for patients with TMD. Ongoing studies are
validating a revision and expansion of the original in-
strument, based in part on the ethical dialectics pro-
posed in the literature and above [26]. Some of the
bioethical issues that need to be incorporated in the new
instrument are highlighted (Table 3).ase [25]
Subjective assessment by the caregiver, overall Fit
Subjective, caregiver (Person)
Subjective, caregiving responsibilities (Environment)
Subjective, caregiving responsibilities (Environment)
Subjective, caregiving responsibilities (Environment)
Subjective, caregiving responsibilities (Environment)
Subjective, caregiving responsibilities (Environment)
Subjective, caregiving responsibilities (Environment)
Subjective, caregiver (Person)
Objective, caregiving responsibilities (Environment)
Objective, caregiving responsibilities (Environment)
Subjective, caregiver (Person)
Objective, caregiver (Person)
Objective, caregiver (Person)
Objective, caregiving responsibilities (Environment)
Table 3 Stakeholder engagement fit general model
Subjective Objective
Stakeholder Perception of the stakeholder’s energy level, mood,
abilities and skills, and willingness to meet the
demands imposed by their engagement in the
clinical decision-making process for patient-targeted
intervention.
Effectiveness in taking on own role as stakeholder, facing
financial hardship, adapting in changing life’s role and
routine, and controlling psycho-emotional strain and stress
associated with the demands imposed by their engagement
in patient-targeted intervention.
Engagement in the clinical
decision-making process
Stakeholder’s understanding and knowledge of the
clinical condition at hand, of the options for treatment,
of the best available evidence (i.e., health literacy).
Bioethical concerns, including privacy, bias, ensuring
“individualized equal care” [27], minimizing “cumulative
incremental risks” [28], and values [29].
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proach to bioethical concerns in translational medicine,
we propose the person-environment fit model to a
patient-evidence-provider best-fit model that is grounded
on the same principles outlined above [2]. In this more
complex approach, eight primary outcomes were identi-
fied (below) to describe the relation among objective and
subjective patients, evidence and providers. These do-
mains are used in order to develop specific criteria for the
stakeholder engagement assessment tool.
1. Patient objective – Evidence objective – Provider
Objective: optimal translational medicine
2. Patient objective – Evidence objective – Provider
Subjective: sub-optimal translational medicine, with
potential bias on the part of the provider
3. Patient objective – Evidence subjective – Provider
subjective: health care based on the evidence, with
added concern of potentially biased provider
4. Patient Objective – Evidence subjective – Provider
objective: health care based on the evidence,
provider unbiased
5. Patient subjective – Evidence Objective – Provider
subjective: although the best available evidence is
used, caveat of bias due subjective patient and
provider
6. Patient subjective – Evidence subjective – Provider
subjective: evidence-based of the evidence, with all
possible drawbacks of subjective assessments
7. Patient subjective – Evidence objective – Provider
objective: attempt is made for translational medicine,
but patient is biased with pre-conceived notions:
provider must help patient “un”learn the misguided
information before the best available evidence can
be given
8. Patient subjective – Evidence subjective – Provider
objective: provider needs to be taught how to gain
access to the best available evidence in order to
carry out translational medicine effectively [2].
Conclusion
Primary areas of bioethical concern subsist in the con-
text of patient-targeted intervention in translational
medicine. They are: (1) selection bias in the samplingprocess, (2) invasiveness of the screening and treatment
protocols, (3) infraction to the fundamental principles of
human rights and human dignity, and (4) reliable process
of research synthesis for obtaining the best available evi-
dence for patient-targeted intervention, and unbiased dis-
semination and utilization in specific clinical settings. The
latter pertains to the domain of translational effectiveness,
which we have discussed previously [30], and involves the
issues of stakeholder engagement assessment and analysis
we have considered here, in line, with the need for “indi-
vidualized equal care” proposed by others [27]. Incontest-
able compelling evidence shows that from a bioethical
standpoint, patients and their representatives have the
right to be included in decisions that pertain to patient-
targeted interventions. It is also self-evident that this priv-
ilege cannot be extended to all stakeholders, and that
stakeholder engagement analysis is needed to contribute
positive impact on the transparency and accountability of
translational science. Therefore, reaching a shared under-
standing of ethical roles and responsibilities amongst
stakeholders require dialogue and reciprocal awareness of
limitations.
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